+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Geographic Atrophy Market Report 2024-2034

  • PDF Icon

    Report

  • 218 Pages
  • October 2024
  • Region: Global
  • Visiongain
  • ID: 6010614
Description Jump to:
Overall world revenue for the Geographic Atrophy Market: In terms of value the market will surpass US$4.50 billion in 2024, the work calculates. The publisher predicts strong revenue growth through to 2034. The work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

The Geographic Atrophy Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Collaborations Among Market Players are Driving the Market Growth

Rising collaborations amongst market players are driving market growth because they combine diverse expertise, resources, and technologies, accelerating the development and commercialisation of innovative treatments. Partnerships allow companies to share risks and costs associated with research and development, access each other's strengths, and enhance their competitive edge. On April 29, 2023, Astellas Pharma Inc. and Iveric Bio, Inc. announced a definitive agreement under which Astellas, through its subsidiary Berry Merger Sub, Inc.

Challenges Associated with GA Treatment Likely to Hamper Market Growth

Geographic atrophy (GA) treatment faces significant challenges, particularly in remote areas with limited healthcare access, leading to delayed detection and treatment. Raising awareness about eye health and regular exams is crucial. Current GA treatments are hindered by the lack of a cure, limited effectiveness, frequent administration, and inability to reverse damage. Advanced imaging technologies and genetic research are essential for accurate diagnosis and targeted therapies. Promising treatments, including gene and stem cell therapies, are in development, but the lack of validated endpoints and failures of late-stage drugs underscore the ongoing difficulties in treating GA.

Key Questions Answered

  • How is the geographic atrophy market evolving?
  • What is driving and restraining the geographic atrophy market?
  • How will each geographic atrophy submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
  • How will the market shares for each geographic atrophy submarket develop from 2024 to 2034?
  • What will be the main driver for the overall market from 2024 to 2034?
  • Will leading geographic atrophy markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the geographic atrophy projects for these leading companies?
  • How will the industry evolve during the period between 2024 and 2034? What are the implications of geographic atrophy projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the geographic atrophy market?
  • Where is the geographic atrophy market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the geographic atrophy market today, and over the next 10 years:

  • This 218-page report provides 80 tables and 144 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them ‚Äì NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2034 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2034, the new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising geographic atrophy prices and recent developments.

Segments Covered in the Report

Type

  • Focal GA
  • Multifocal GA
  • Confluent GA

Drugs

  • Pegcetacoplan (SYFOVRE)
  • Avacincaptad pegol (IZERVAY)
  • Others

Route of Administration

  • Intravitreal Route
  • Intravenous Route
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce Pharmacies
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 10 leading national markets:

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Rest of Asia Pacific

Rest of the World (RoW)

The report also includes profiles for some of the leading companies in the Geographic Atrophy Market, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

  • Alkeus Pharmaceuticals, Inc.
  • Apellis Pharmaceuticals
  • Astellas Pharma Inc.
  • AstraZeneca
  • Bausch + Lomb
  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche Ltd.
  • Ionis Pharmaceuticals
  • Johnson & Johnson
  • Santen Pharmaceutical Co., Ltd.

How will the Geographic Atrophy Market report help you?

In summary, the 210+ page report provides you with the following knowledge:
  • Revenue forecasts to 2034 for Geographic Atrophy Market Market, with forecasts for type, drugs, route of administration, and distribution channel, each forecast at a global and regional level ‚Äì discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2034 for five regional and 10 key national markets ‚Äì See forecasts for the Geographic Atrophy Market market in North America, Europe, Asia-Pacific, and RoW. Also forecasted is the market in the U.S., Canada, Germany, France, UK, Italy, France, Spain, China, India, and Japan among other prominent economies.
  • Prospects for established firms and those seeking to enter the market ‚Äì including company profiles for 10 of the major companies involved in the Geographic Atrophy Market.
Find quantitative and qualitative analyses with independent predictions. Receive information that only this report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With this new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how this work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Geographic Atrophy Market, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Geographic Atrophy Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About the Publisher
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.3 Impact Analysis
3.3.1 Market Driving Factors
3.3.1.1 New Product Launches is Driving the Market Growth
3.3.1.2 Rising Geriatric Population
3.3.1.3 Growing Prevalence of Geographic Atrophy
3.3.2 Market Restraining Factors
3.3.2.1 High Cost of Novel Drugs is Restraining the Growth of the GA Market
3.3.2.2 Challenges Associated with the Geographic Atrophy Treatment
3.3.3 Market Opportunities
3.3.3.1 Promising Product Pipeline
3.3.3.2 Collaborations Amongst Market Players
3.3.3.3 Increase in R&D Investments by Pharmaceutical & Biopharmaceutical Companies
3.4 Regulatory Framework
3.5 Emerging Markets and Megatrends
3.6 Porter's Five Forces Analysis
3.6.1 Bargaining Power of Suppliers
3.6.2 Bargaining Power of Buyers
3.6.3 Competitive Rivalry
3.6.4 Threat from Substitutes
3.6.5 Threat of New Entrants
3.7 PEST Analysis
4 Geographic Atrophy Market Analysis by Type
4.1 Key Findings
4.2 Type Segment: Market Attractiveness Index
4.3 Geographic Atrophy Market Size Estimation and Forecast by Type
4.4 Focal GA
4.4.1 Market Size by Region, 2024-2034 (US$ Million)
4.4.2 Market Share by Region, 2024 & 2034 (%)
4.5 Multifocal GA
4.5.1 Market Size by Region, 2024-2034 (US$ Million)
4.5.2 Market Share by Region, 2024 & 2034 (%)
4.6 Confluent GA
4.6.1 Market Size by Region, 2024-2034 (US$ Million)
4.6.2 Market Share by Region, 2024 & 2034 (%)
5 Geographic Atrophy Market Analysis by Drugs
5.1 Key Findings
5.2 Drugs Segment: Market Attractiveness Index
5.3 Geographic Atrophy Market Size Estimation and Forecast by Drugs
5.4 Pegcetacoplan (SYFOVRE)
5.4.1 Market Size by Region, 2024-2034 (US$ Million)
5.4.2 Market Share by Region, 2024 & 2034 (%)
5.5 Avacincaptad pegol (IZERVAY)
5.5.1 Market Size by Region, 2024-2034 (US$ Million)
5.5.2 Market Share by Region, 2024 & 2034 (%)
5.6 Others
5.6.1 Market Size by Region, 2024-2034 (US$ Million)
5.6.2 Market Share by Region, 2024 & 2034 (%)
6 Geographic Atrophy Market Analysis by Route of Administration
6.1 Key Findings
6.2 Route of Administration Segment: Market Attractiveness Index
6.3 Geographic Atrophy Market Size Estimation and Forecast by Route of Administration
6.4 Intravitreal Route
6.4.1 Market Size by Region, 2024-2034 (US$ Million)
6.4.2 Market Share by Region, 2024 & 2034 (%)
6.5 Intravenous Route
6.5.1 Market Size by Region, 2024-2034 (US$ Million)
6.5.2 Market Share by Region, 2024 & 2034 (%)
6.6 Others
6.6.1 Market Size by Region, 2024-2034 (US$ Million)
6.6.2 Market Share by Region, 2024 & 2034 (%)
7 Geographic Atrophy Market Analysis by Distribution Channel
7.1 Key Findings
7.2 Distribution Channel Segment: Market Attractiveness Index
7.3 Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel
7.4 Hospital Pharmacies
7.4.1 Market Size by Region, 2024-2034 (US$ Million)
7.4.2 Market Share by Region, 2024 & 2034 (%)
7.5 Retail Pharmacies
7.5.1 Market Size by Region, 2024-2034 (US$ Million)
7.5.2 Market Share by Region, 2024 & 2034 (%)
7.6 E-Commerce Pharmacies
7.6.1 Market Size by Region, 2024-2034 (US$ Million)
7.6.2 Market Share by Region, 2024 & 2034 (%)
8 Geographic Atrophy Market Analysis by Region
8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast
9 North America Geographic Atrophy Market Analysis
9.1 Key Findings
9.2 North America Geographic Atrophy Market Attractiveness Index
9.3 North America Geographic Atrophy Market by Country, 2024, 2029 & 2034 (US$ Million)
9.4 North America Geographic Atrophy Market Size Estimation and Forecast by Country
9.5 North America Geographic Atrophy Market Size Estimation and Forecast by Type
9.6 North America Geographic Atrophy Market Size Estimation and Forecast by Drugs
9.7 North America Geographic Atrophy Market Size Estimation and Forecast by Route of Administration
9.8 North America Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel
9.9 U.S. Geographic Atrophy Market Analysis
9.10 Canada Geographic Atrophy Market Analysis
10 Europe Geographic Atrophy Market Analysis
10.1 Key Findings
10.2 Europe Geographic Atrophy Market Attractiveness Index
10.3 Europe Geographic Atrophy Market by Country, 2024, 2029 & 2034 (US$ Million)
10.4 Europe Geographic Atrophy Market Size Estimation and Forecast by Country
10.5 Europe Geographic Atrophy Market Size Estimation and Forecast by Type
10.6 Europe Geographic Atrophy Market Size Estimation and Forecast by Drugs
10.7 Europe Geographic Atrophy Market Size Estimation and Forecast by Route of Administration
10.8 Europe Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel
10.9 Germany Geographic Atrophy Market Analysis
10.10 UK Geographic Atrophy Market Analysis
10.11 France Geographic Atrophy Market Analysis
10.12 Italy Geographic Atrophy Market Analysis
10.13 Spain Geographic Atrophy Market Analysis
10.14 Rest of Europe Geographic Atrophy Market Analysis
11 Asia Geographic Atrophy Market Analysis
11.1 Key Findings
11.2 Asia Geographic Atrophy Market Attractiveness Index
11.3 Asia Geographic Atrophy Market by Country, 2024, 2029 & 2034 (US$ Million)
11.4 Asia Geographic Atrophy Market Size Estimation and Forecast by Country
11.5 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Type
11.6 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Drugs
11.7 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Route of Administration
11.8 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel
11.9 Japan Geographic Atrophy Market Analysis
11.10 China Geographic Atrophy Market Analysis
11.11 India Geographic Atrophy Market Analysis
11.12 Rest of Asia Geographic Atrophy Market Analysis
12 Rest of World Geographic Atrophy Market Analysis
12.1 Key Findings
12.2 Rest of World Geographic Atrophy Market Size Estimation and Forecast by Type
12.3 Rest of World Geographic Atrophy Market Size Estimation and Forecast by Drugs
12.4 Rest of World Geographic Atrophy Market Size Estimation and Forecast by Route of Administration
12.5 Rest of World Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel
13 Company Profiles
13.1 Company Share Analysis, 2023
13.2 Strategic Outlook
13.3 Alkeus Pharmaceuticals, Inc.
13.3.1 Company Snapshot
13.3.2 Company Overview
13.3.3 Product Benchmarking
13.3.4 Strategic Outlook
13.3.5 SWOT Analysis
13.4 Bausch + Lomb
13.4.1 Company Snapshot
13.4.2 Company Overview
13.4.3 Financial Analysis
13.4.3.1 Net Revenue, 2019-2023
13.4.3.2 R&D, 2019-2023
13.4.3.3 Regional Market Shares, 2023
13.4.3.4 Business Segment Market Shares, 2023
13.4.4 Product Benchmarking
13.4.5 Strategic Outlook
13.4.6 SWOT Analysis
13.5 Ionis Pharmaceuticals
13.5.1 Company Snapshot
13.5.2 Company Overview
13.5.3 Financial Analysis
13.5.3.1 Net Revenue, 2019-2023
13.5.3.2 R&D, 2019-2023
13.5.3.3 Regional Market Shares, 2023
13.5.4 Product Benchmarking
13.5.5 Strategic Outlook
13.6 Santen Pharmaceutical Co., Ltd.
13.6.1 Company Snapshot
13.6.2 Company Overview
13.6.3 Financial Analysis
13.6.3.1 Net Revenue, 2019-2023
13.6.3.2 R&D, 2019-2023
13.6.3.3 Regional Market Shares, 2023
13.6.4 Product Benchmarking
13.6.5 Strategic Outlook
13.7 Astellas Pharma Inc.
13.7.1 Company Snapshot
13.7.2 Company Overview
13.7.3 Financial Analysis
13.7.3.1 Net Revenue, 2019-2023
13.7.3.2 R&D, 2019-2023
13.7.3.3 Regional Market Shares, 2023
13.7.4 Product Benchmarking
13.7.5 Strategic Outlook
13.7.6 SWOT Analysis
13.8 Boehringer Ingelheim International GmbH
13.8.1 Company Snapshot
13.8.2 Company Overview
13.8.3 Financial Analysis
13.8.3.1 Net Revenue, 2019-2023
13.8.3.2 R&D, 2019-2023
13.8.3.3 Regional Market Shares, 2023
13.8.3.4 Business Segment Market Shares, 2023
13.8.4 Product Benchmarking
13.8.5 Strategic Outlook
13.8.6 SWOT Analysis
13.9 F. Hoffmann-La Roche Ltd.
13.9.1 Company Snapshot
13.9.2 Company Overview
13.9.3 Financial Analysis
13.9.3.1 Net Revenue, 2019-2023
13.9.3.2 R&D, 2019-2023
13.9.3.3 Business Segment Market Shares, 2023
13.9.4 Product Benchmarking
13.9.5 Strategic Outlook
13.9.6 SWOT Analysis
13.10 Apellis Pharmaceuticals
13.10.1 Company Snapshot
13.10.2 Company Overview
13.10.3 Financial Analysis
13.10.3.1 Net Revenue, 2019-2023
13.10.3.2 R&D, 2019-2023
13.10.3.3 Business Segment Market Shares, 2023
13.10.4 Product Benchmarking
13.10.5 Strategic Outlook
13.10.6 SWOT Analysis
13.11 AstraZeneca
13.11.1 Company Snapshot
13.11.2 Company Overview
13.11.3 Financial Analysis
13.11.3.1 Net Revenue, 2019-2023
13.11.3.2 R&D, 2019-2023
13.11.3.3 Regional Market Shares, 2023
13.11.3.4 Business Segment Market Shares, 2023
13.11.4 Product Benchmarking
13.11.5 Strategic Outlook
13.11.6 SWOT Analysis
13.12 Johnson & Johnson
13.12.1 Company Snapshot
13.12.2 Company Overview
13.12.3 Financial Analysis
13.12.3.1 Net Revenue, 2019-2023
13.12.3.2 R&D, 2019-2023
13.12.3.3 Regional Market Shares, 2023
13.12.3.4 Business Segment Market Shares, 2023
13.12.4 Product Benchmarking
13.12.5 Strategic Outlook
14 Conclusion and Recommendations
14.1 Concluding Remarks
14.2 Recommendations for Market Players
List of Tables
Table 1 Geographic Atrophy Market Snapshot, 2024 & 2034 (US$ Million, CAGR %)
Table 2 Geographic Atrophy Market Forecast by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 3 Focal GA Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 4 Multifocal GA Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 5 Confluent GA Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 6 Geographic Atrophy Market Forecast by Drugs, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 7 Pegcetacoplan (SYFOVRE) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 8 Avacincaptad pegol (IZERVAY) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 9 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 10 Geographic Atrophy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 11 Intravitreal Route Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 12 Intravenous Route Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 13 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 14 Geographic Atrophy Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 15 Hospital Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 16 Retail Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 17 E-Commerce Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 18 Geographic Atrophy Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 19 North America Geographic Atrophy Market Forecast by Country, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 20 North America Geographic Atrophy Market Forecast by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 21 North America Geographic Atrophy Market Forecast by Drugs, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 22 North America Geographic Atrophy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 23 North America Geographic Atrophy Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 24 U.S. Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 25 Canada Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 26 Europe Geographic Atrophy Market Forecast by Country, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 27 Europe Geographic Atrophy Market Forecast by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 28 Europe Geographic Atrophy Market Forecast by Drugs, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 29 Europe Geographic Atrophy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 30 Europe Geographic Atrophy Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 31 Germany Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 32 UK Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 33 France Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 34 Italy Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 35 Spain Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 36 Rest of Europe Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 37 Asia Geographic Atrophy Market Forecast by Country, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 38 Asia Pacific Geographic Atrophy Market Forecast by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 39 Asia Pacific Geographic Atrophy Market Forecast by Drugs, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 40 Asia Pacific Geographic Atrophy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 41 Asia Pacific Geographic Atrophy Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 42 Japan Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 43 China Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 44 India Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 45 Rest of Asia Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 46 Rest of World Geographic Atrophy Market Forecast by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 47 Rest of World Geographic Atrophy Market Forecast by Drugs, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 48 Rest of World Geographic Atrophy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 49 Rest of World Geographic Atrophy Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 50 Strategic Outlook
Table 51 Alkeus Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 52 Alkeus Pharmaceuticals, Inc.: Product Benchmarking
Table 53 Alkeus Pharmaceuticals, Inc.: Strategic Outlook
Table 54 Bausch + Lomb: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 55 Bausch + Lomb: Product Benchmarking
Table 56 Bausch + Lomb: Strategic Outlook
Table 57 Ionis Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 58 Ionis Pharmaceuticals: Product Benchmarking
Table 59 Ionis Pharmaceuticals: Strategic Outlook
Table 60 Santen Pharmaceutical Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 61 Santen Pharmaceutical Co., Ltd.: Product Benchmarking
Table 62 Santen Pharmaceutical Co., Ltd.: Strategic Outlook
Table 63 Astellas Pharma Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 64 Astellas Pharma Inc.: Product Benchmarking
Table 65 Astellas Pharma Inc.: Strategic Outlook
Table 66 Boehringer Ingelheim International GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 67 Boehringer Ingelheim International GmbH: Product Benchmarking
Table 68 Boehringer Ingelheim International GmbH: Strategic Outlook
Table 69 F. Hoffmann-La Roche Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 70 F. Hoffmann-La Roche Ltd.: Product Benchmarking
Table 71 F. Hoffmann-La Roche Ltd.: Strategic Outlook
Table 72 Apellis Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 73 Apellis Pharmaceuticals: Product Benchmarking
Table 74 Apellis Pharmaceuticals: Strategic Outlook
Table 75 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 76 AstraZeneca: Product Benchmarking
Table 77 AstraZeneca: Strategic Outlook
Table 78 Johnson & Johnson: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 79 Johnson & Johnson: Product Benchmarking
Table 80 Johnson & Johnson: Strategic Outlook
List of Figures
Figure 1 Geographic Atrophy Market Segmentation
Figure 2 Geographic Atrophy Market by Type: Market Attractiveness Index
Figure 3 Geographic Atrophy Market Attractiveness Index by Drugs
Figure 4 Geographic Atrophy Market Attractiveness Index by Route of Administration
Figure 5 Geographic Atrophy Market Attractiveness Index by Distribution Channel Range
Figure 6 Geographic Atrophy Market Attractiveness Index by Region
Figure 7 Geographic Atrophy Market: Market Dynamics
Figure 8 Geographic Atrophy Market: Impact Analysis
Figure 9 Geographic Atrophy Market: Porter's Five Forces Analysis
Figure 10 Geographic Atrophy Market: PEST Analysis
Figure 11 Geographic Atrophy Market by Type: Market Attractiveness Index
Figure 12 Geographic Atrophy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 13 Geographic Atrophy Market Forecast by Type, 2024, 2029, 2034 (%)
Figure 14 Focal GA Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 15 Focal GA Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 16 Multifocal GA Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 17 Multifocal GA Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 18 Confluent GA Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 19 Confluent GA Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 20 Geographic Atrophy Market by Drugs: Market Attractiveness Index
Figure 21 Geographic Atrophy Market Forecast by Drugs, 2024-2034 (US$ Million, AGR %)
Figure 22 Geographic Atrophy Market Forecast by Drugs, 2024, 2029, 2034 (%)
Figure 23 Pegcetacoplan (SYFOVRE) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 24 Pegcetacoplan (SYFOVRE) Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 25 Avacincaptad pegol (IZERVAY) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 26 Avacincaptad pegol (IZERVAY) Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 27 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 28 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 29 Geographic Atrophy Market by Route of Administration: Market Attractiveness Index
Figure 30 Geographic Atrophy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
Figure 31 Geographic Atrophy Market Forecast by Route of Administration, 2024, 2029, 2034 (%)
Figure 32 Intravitreal Route Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 33 Intravitreal Route Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 34 Intravenous Route Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 35 Intravenous Route Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 36 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 37 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 38 Geographic Atrophy Market by Distribution Channel: Market Attractiveness Index
Figure 39 Geographic Atrophy Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 40 Geographic Atrophy Market Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 41 Hospital Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 42 Hospital Pharmacies Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 43 Retail Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 44 Retail Pharmacies Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 45 E-Commerce Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 46 E-Commerce Pharmacies Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 47 Geographic Atrophy Market Forecast by Region 2024 and 2034 (Revenue, CAGR%)
Figure 48 Geographic Atrophy Market Share Forecast by Region 2024, 2029, 2034 (%)
Figure 49 Geographic Atrophy Market by Region, 2024-2034 (US$ Million, AGR %)
Figure 50 North America Geographic Atrophy Market Attractiveness Index
Figure 51 North America Geographic Atrophy Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 52 North America Geographic Atrophy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 53 North America Geographic Atrophy Market Share Forecast by Country, 2024 & 2034 (%)
Figure 54 North America Geographic Atrophy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 55 North America Geographic Atrophy Market Share Forecast by Type, 2024 & 2034 (%)
Figure 56 North America Geographic Atrophy Market Forecast by Drugs, 2024-2034 (US$ Million, AGR %)
Figure 57 North America Geographic Atrophy Market Share Forecast by Drugs, 2024 & 2034 (%)
Figure 58 North America Geographic Atrophy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
Figure 59 North America Geographic Atrophy Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 60 North America Geographic Atrophy Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 61 North America Geographic Atrophy Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 62 U.S. Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 63 Canada Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 64 Europe Geographic Atrophy Market Attractiveness Index
Figure 65 Europe Geographic Atrophy Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 66 Europe Geographic Atrophy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 67 Europe Geographic Atrophy Market Share Forecast by Country, 2024 & 2034 (%)
Figure 68 Europe Geographic Atrophy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 69 Europe Geographic Atrophy Market Share Forecast by Type, 2024 & 2034 (%)
Figure 70 Europe Geographic Atrophy Market Forecast by Drugs, 2024-2034 (US$ Million, AGR %)
Figure 71 Europe Geographic Atrophy Market Share Forecast by Drugs, 2024 & 2034 (%)
Figure 72 Europe Geographic Atrophy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
Figure 73 Europe Geographic Atrophy Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 74 Europe Geographic Atrophy Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 75 Europe Geographic Atrophy Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 76 Germany Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 77 UK Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 78 France Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 79 Italy Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 80 Spain Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 81 Rest of Europe Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 82 Asia Geographic Atrophy Market Attractiveness Index
Figure 83 Asia Geographic Atrophy Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 84 Asia Geographic Atrophy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 85 Asia Geographic Atrophy Market Share Forecast by Country, 2024 & 2034 (%)
Figure 86 Asia Pacific Geographic Atrophy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 87 Asia Pacific Geographic Atrophy Market Share Forecast by Type, 2024 & 2034 (%)
Figure 88 Asia Pacific Geographic Atrophy Market Forecast by Drugs, 2024-2034 (US$ Million, AGR %)
Figure 89 Asia Pacific Geographic Atrophy Market Share Forecast by Drugs, 2024 & 2034 (%)
Figure 90 Asia Pacific Geographic Atrophy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
Figure 91 Asia Pacific Geographic Atrophy Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 92 Asia Pacific Geographic Atrophy Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 93 Asia Pacific Geographic Atrophy Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 94 Japan Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 95 China Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 96 India Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 97 Rest of Asia Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 98 Rest of World Geographic Atrophy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 99 Rest of World Geographic Atrophy Market Share Forecast by Type, 2024 & 2034 (%)
Figure 100 Rest of World Geographic Atrophy Market Forecast by Drugs, 2024-2034 (US$ Million, AGR %)
Figure 101 Rest of World Geographic Atrophy Market Share Forecast by Drugs, 2024 & 2034 (%)
Figure 102 Rest of World Geographic Atrophy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
Figure 103 Rest of World Geographic Atrophy Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 104 Rest of World Geographic Atrophy Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 105 Rest of World Geographic Atrophy Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 106 Geographic Atrophy Market: Company Share Analysis, 2023
Figure 107 Alkeus Pharmaceuticals, Inc.: SWOT Analysis
Figure 108 Bausch + Lomb: Net Revenue, 2019-2023 (US$ Million, AGR%)
Figure 109 Bausch + Lomb: R&D, 2019-2023 (US$ Million, AGR%)
Figure 110 Bausch + Lomb: Regional Market Shares, 2023
Figure 111 Bausch + Lomb: Business Segment Market Shares, 2023
Figure 112 Bausch + Lomb: SWOT Analysis
Figure 113 Ionis Pharmaceuticals: Net Revenue, 2019-2023 (US$ Million, AGR%)
Figure 114 Ionis Pharmaceuticals: R&D, 2019-2023 (US$ Million, AGR %)
Figure 115 Ionis Pharmaceuticals: Regional Market Shares, 2023
Figure 116 Santen Pharmaceutical Co., Ltd.: Net Revenue, 2019-2023 (US$ Million, AGR %)
Figure 117 Santen Pharmaceutical Co., Ltd.: R&D, 2019-2023 (US$ Million, AGR %)
Figure 118 Santen Pharmaceutical Co., Ltd.: Regional Market Shares, 2023
Figure 119 Astellas Pharma Inc.: Net Revenue, 2019-2023 (US$ Million, AGR %)
Figure 120 Astellas Pharma Inc.: R&D, 2019-2023 (US$ Million, AGR %)
Figure 121 Astellas Pharma Inc.: Regional Market Shares, 2023
Figure 122 Astellas Pharma Inc.: SWOT Analysis
Figure 123 Boehringer Ingelheim International GmbH: Net Revenue, 2019-2023 (US$ Million, AGR %)
Figure 124 Boehringer Ingelheim International GmbH: R&D, 2019-2023 (US$ Million, AGR %)
Figure 125 Boehringer Ingelheim International GmbH: Regional Market Shares, 2023
Figure 126 Boehringer Ingelheim International GmbH: Business Segment Market Shares, 2023
Figure 127 Boehringer Ingelheim International GmbH: SWOT Analysis
Figure 128 F. Hoffmann-La Roche Ltd.: Net Revenue, 2019-2023 (US$ Million, AGR %)
Figure 129 F. Hoffmann-La Roche Ltd.: R&D, 2019-2023 (US$ Million, AGR %)
Figure 130 F. Hoffmann-La Roche Ltd.: Business Segment Market Shares, 2023
Figure 131 F. Hoffmann-La Roche Ltd.: SWOT Analysis
Figure 132 Apellis Pharmaceuticals: Net Revenue, 2019-2023 (US$ Million, AGR %)
Figure 133 Apellis Pharmaceuticals: R&D, 2019-2023 (US$ Million, AGR %)
Figure 134 Apellis Pharmaceuticals: Business Segment Market Shares, 2023
Figure 135 Apellis Pharmaceuticals: SWOT Analysis
Figure 136 AstraZeneca: Net Revenue, 2019-2023 (US$ Million, AGR %)
Figure 137 AstraZeneca: R&D, 2019-2023 (US$ Million, AGR %)
Figure 138 AstraZeneca: Regional Market Shares, 2023
Figure 139 AstraZeneca: Business Segment Market Shares, 2023
Figure 140 AstraZeneca: SWOT Analysis
Figure 141 Johnson & Johnson: Net Revenue, 2019-2023 (US$ Million, HUMOUR)
Figure 142 Johnson & Johnson: R&D, 2019-2023 (US$ Million, HUMOUR)
Figure 143 Johnson & Johnson: Regional Market Shares, 2023
Figure 144 Johnson & Johnson: Business Segment Market Shares, 2023

Companies Mentioned

  • Alkeus Pharmaceuticals, Inc.
  • Apellis Pharmaceuticals
  • Astellas Pharma Inc.
  • AstraZeneca
  • Bausch + Lomb
  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche Ltd.
  • Ionis Pharmaceuticals
  • Johnson & Johnson
  • Santen Pharmaceutical Co., Ltd.
  • AffaMed Therapeutics
  • Alexion
  • Allegro Ophthalmics
  • Astellas US Holding, Inc.
  • Aviceda Therapeutics
  • Bayer
  • Bayer Yakuhin, Ltd.
  • Berry Merger Sub, Inc.
  • CDR-Life
  • Central Drugs Standards Control Organization, India (CDSCO)
  • CRISPR Therapeutics
  • Editas Medicine
  • EyePoint Pharmaceuticals, Inc.
  • Eyestem Research
  • Genetech
  • Ikerian AG
  • Inflammasome Therapeutics
  • Iveric Bio
  • Modulight Corporation
  • NGM Bio
  • Novartis
  • Novartis Canada
  • Rallybio Corporation
  • RetinAI Inc
  • Roche Canada
  • Stealth BioTherapeutics
  • Australian Register of Therapeutic Goods (ARTG)
  • CBRE
  • Centers for Medicare & Medicaid Services
  • China Government
  • China's National Medical Products Administration (NMPA)
  • Committee for Medicinal Products for Human Use (CHMP)
  • European Commission
  • European Medicines Agency (EMA)
  • Health Canada
  • Health Products and Food Branch (HPFB)
  • International Agency for the Prevention of Blindness (IAPB)
  • Italian Association of Ophthalmologists (AIMO),
  • Italian Society of Ophthalmology (SOI)
  • Italian Union of the Blind (UICI)
  • John Wiley & Sons
  • Journal of the American Medical Association (JAMA)
  • Macula Retina Association (Asociaci√≥n M√°cula Retina)
  • Ministry of Health, France
  • Moorfields Eye Hospital
  • National Center for Biotechnology Information (NCBI)
  • National Institutes of Health (NIH)
  • Pharmaceuticals and Medical Devices Agency (PMDA)
  • Societ√† Italiana di Scienze Oftalmologiche (S.I.S.O.)
  • Spanish National Organization of the Blind (Organizaci√≥n Nacional de Ciegos Espa√±oles - ONCE)
  • Therapeutic Goods Administration (TGA)
  • U.S. Food and Drug Administration (FDA)
  • United Nations
  • University College London
  • University of Cologne
  • University of Toronto
  • World Academy of Science, Engineering, and Technology

Related Topics

Related Reports

Dry Age-Related Macular Degeneration - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Dry Age-Related Macular Degeneration - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 244 Pages
  • Global
From
Geographic Atrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Geographic Atrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 131 Pages
  • Global
From
Dry Age-Related Macular Degeneration - Epidemiology Forecast - 2034 - Product Image

Dry Age-Related Macular Degeneration - Epidemiology Forecast - 2034

  • Report
  • 122 Pages
  • Global
From
Hereditary Optic Atrophies Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Hereditary Optic Atrophies Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 129 Pages
  • Global
From
Geographic Atrophy Market Report and Forecast 2024-2032 - Product Image

Geographic Atrophy Market Report and Forecast 2024-2032

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.